Polymyalgia rheumatica, Arteriitis temporalis, Riesenzell-Arteriitis: Begriffsbestimmung und Epidemiologie

Zusammenfassung

Die Polymyalgia rheumatica (PMR) und die Arteriitis temporalis (AT) als Sonderform der Riesenzellarteriitiden (RZA) sind miteinander verwandte Krankheitsbilder. Als typische Erkrankungen des höheren Lebensalters wird ihre Bedeutung in einer alternden Gesellschaft künftig eher zunehmen. Die PMR ist unter den über 50-Jährigen mit einer jährlichen Inzidenz von fast 60 Fällen auf 100 000 häufiger als die AT. Beiden Erkrankungen ist – sowohl in den USA als auch in Europa – ein Nord-Süd-Gefälle eigen mit höheren Prävalenzraten in den nördlichen Regionen.

Abstract

Polymyalgia rheumatica and temporal arteritis are related entities. Both diseases strongly prefer patients of higher age, indicating that their relevance will increase in an aging society. Among persons older than 50 years, the incidence of polymyalgia rheumatica is higher than that of temporal arteritis, reaching almost 60 cases per 100 000 inhabitants. In the U. S. A. as well as in Europe, the incidence of both diseases is higher in northern regions.·

Schlüsselwörter

Polymyalgia rheumatica - Arteriitis temporalis - Riesenzellarteriitis - Prävalenz - Inzidenz

Key words

polymyalgia rheumatica - temporal arteritis - giant cell arteritis - prevalence - incidence

• Literatur

• 1 Barber HS. Myalgic syndrome with constitutional effects; polymyalgia rheumatica. Annals of the rheumatic diseases 1957; 16: 230-237
• 2 Horton BT. Temporal arteritis; report of 39 cases. Proceedings [of the] annual meeting Central Society for Clinical Research (US) 1946; 19: 78
• 3 Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. Annals of internal medicine 2003; 139: 505-515
• 4 Gran JT, Myklebust G. The incidence of polymyalgia rheumatica and temporal arteritis in the county of Aust Agder, south Norway: a prospective study 1987–94. The Journal of rheumatology 1997; 24: 1739-1743
• 5 Salvarani C, Gabriel SE, O’Fallon WM et al. Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970–1991. Arthritis and rheumatism 1995; 38: 369-373
• 6 Cimmino MA, Zaccaria A. Epidemiology of polymyalgia rheumatica. Clinical and experimental rheumatology 2000; 18: S9-S11
• 7 Lawrence RC, Felson DT, Helmick CG et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis and rheumatism 2008; 58: 26-35
• 8 Juby A, Davis P. An evaluation of the impact of seniors on a rheumatology referral clinic: demographics and pharmacotherapy. Clinical rheumatology 2011; 30: 1507-1509
• 9 Bernatsky S, Linehan T, Hanly JG. The accuracy of administrative data diagnoses of systemic autoimmune rheumatic diseases. The Journal of rheumatology 2011; 38: 1612-1616
• 10 Liozon E, Ouattara B, Rhaiem K et al. Familial aggregation in giant cell arteritis and polymyalgia rheumatica: a comprehensive literature review including 4 new families. Clinical and experimental rheumatology 2009; 27: S89-S94
• 11 Borchers AT, Gershwin ME. Giant cell arteritis: A review of classification, pathophysiology, geoepidemiology and treatment. Autoimmunity reviews 2012;
• 12 Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis research & therapy 2009; 11: 229
• 13 Duhaut P, Pinede L, Bornet H et al. Biopsy proven and biopsy negative temporal arteritis: differences in clinical spectrum at the onset of the disease. Groupe de Recherche sur l’Arterite a Cellules Geantes. Annals of the rheumatic diseases 1999; 58: 335-341
• 14 Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008; 372: 234-245